for relapsed low grade lymphoma and relapsed multiple myeloma (Bendamustine is not licensed in these indications)

 for NICE TA423

 for first line treatment of recurrent or metastatic cervical cancer in combination with chemotherapy, third line treatment of glioma in childhood and first line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

 for the treatment of bortezomib naive relapsed multiple myeloma

 for relapsed or refractory CD30+ Hodgkin's lymphona after at least 2 previous therapies and cannot have autologous stem cell translplant or multi-agent chemotherapy

 for relapsed or refractory CD30+ Hodgkin's lymphona after autologous stem cell transplant and for relapsed or refractory systemic large cell lymphoma

 for NICE TA529 if the conditions in the managed access agreement are followed.

 for NICE TA406 and NICE TA422

 for NICE TA426

 for NICE TA421, TA432 and TA449

• For use with everolimus

• When prescribing, dispensing or administering, check that this is the correct preparation - trastuzumab emtansine and trastuzumab are NOT interchangeable. 

• When prescribing, dispensing or administering, check that this is the correct preparation - trastuzumab emtansine and trastuzumab are NOT interchangeable.